Drug Discovery Today

NOVEMBER 24, 2022

Over the last decade, co-crystallization has become an attractive alternative to improve the physiochemical properties of drugs without affecting their pharmacology. As a result of the pharmaceutical benefits co-crystals exhibit, industrial interest is on the rise. Here Dr. Thomas Kendall, application specialist at crystallization and solid-state specialist Technobis Crystallization Systems, gives a perspective on the benefits of co-crystals and explains how they can be screened.

Drug Development 153

Drug Development Drugs Pharmaceuticals 153

Chemical Biology and Drug Design

NOVEMBER 22, 2022

Scomberomorus niphonius is the fish eaten worldwide. In this study, we extracted phospholipids from these fish bones using an advanced supercritical CO 2 extraction technique and tested them against neuroblastoma and normal (HUVEC) cells. The molecular findings indicate phospholipids have an apoptotic activity in neuroblastoma. Abstract Among various types children's health challenges, neuroblastoma is the most serious solid neoplasm forming outside the cranium.

DNA 100

DNA Research 100

Antidote

NOVEMBER 21, 2022

Mitral valve regurgitation, also known as mitral regurgitation, mitral insufficiency, or mitral incompetence, is the most common type of heart valve disease , affecting more than 2% of the population. Though mild mitral valve regurgitation does not usually cause issues, it is a condition that can worsen with time and lead to more severe symptoms. Below, we will be looking at what this condition is, what the common causes are, and some symptoms of mitral valve regurgitation that are helpful to kn

Disease 98

Disease 98

Drug Patent Watch

NOVEMBER 25, 2022

Annual Drug Patent Expirations for FYARRO Fyarro is a drug marketed by Aadi and is included in one NDA. There are four patents protecting this drug. This drug has one…. The post New patent for AADI drug FYARRO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Discovery Today

NOVEMBER 21, 2022

Last week, Shionogi partnered with the Active Citizenship Network and members of the European Parliament (MEPs) to host an EU Parliament event calling for collaboration to drive policy change and implementation in the fight against antimicrobial resistance (AMR) within the EU and member states. Urgent action is needed to encourage and support the discovery and development of novel antibiotics as well as access models that reward innovation and appropriate use to address the growing threat of AMR

100

100

The Open Targets Blog

NOVEMBER 24, 2022

The latest release of the Platform — 22.11 — is now available at platform.opentargets.org. Key points In addition to continuous updates from our data providers, we have introduced the following new features: Gene burden data for Parkinson’s disease Updated classifications for clinical trial stop reasons Variant functional consequences, available to browse in the Gene2Phenotype and Orphanet widgets Key stats Metric Count Targets 62,678 Diseases 22,274 Drugs 12,854 Evidence 14

Clinical Trials 52

Clinical Trials Trials Disease Production 52

Drug Patent Watch

NOVEMBER 23, 2022

Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. There are four patents protecting this drug. This drug has forty-four…. The post New patent for Beigene drug BRUKINSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

ProRelix Research

NOVEMBER 23, 2022

Biological products have unlocked the potential for the management of several diseases such as cancers and autoimmune diseases for which treatment with small molecule, chemically synthesized drug molecules remain suboptimal. […]. The post Biosimilar Clinical Trials and US FDA Guidance appeared first on ProRelix Research.

Clinical Trials 52

Clinical Trials Biosimilars FDA Trials 52

PPD

NOVEMBER 21, 2022

The medical communication experts at Thermo Fisher Scientific ’s PPD clinical research business were not satisfied with basic patient satisfaction data to inform our clients’ medical communication strategies. So, we went straight to the source: In December 2021, we directly surveyed 400 European and United States patients on their preferences for medical communications.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Pharmaceuticals Production 52

Reprocell

NOVEMBER 21, 2022

Resistance arteries are a group of blood vessels that regulate up to 90% of peripheral vascular resistance. 1 There are three types of resistance vessels in humans: precapillary sphincters, arterioles, and small arteries. 2 They are important for controlling blood flow to vital organs, such as the heart (coronary arteries) and the brain (cerebral resistance arteries) so are often considered in cardiovascular safety studies. 1,3 In the following article, we have summarized the physiology of resis

Regulations 52

Regulations Disease Drugs 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

NOVEMBER 23, 2022

Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are nineteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

sptlabtech

NOVEMBER 21, 2022

In this article, Chris Waddling , head of our North American FAS Team, writes about his experience managing a core facility for crystallography prior to joining SPT Labtech and the benefits of automated and miniaturized workflows. Miniaturizing crystallization experiments In my previous life as a manager of a crystallography core facility, one of my duties was to find the latest equipment that would remove hurdles in the way of my users' progress toward their scientific goals.

Laboratories 52

Laboratories Engineering Research 52

DrugBaron

NOVEMBER 22, 2022

Proteomics – examining the panoply of proteins within a complex sample – has been around much longer than the word we use today to describe it. Proteomics the word was coined in around 1997 as a portmanteau coupling the now-ubiquitous “omics” suffix to the word protein. But two decades earlier two-dimensional gel electrophoresis was the cutting-edge technology that first visualised the “complete” catalogue of proteins in a sample, such as a cell lysate or blood sample.

Bioinformatics 100

Bioinformatics Regulations Molecular Biology Engineering 100

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 23, 2022

To Save Lives, We Must Dismantle Stigma at the Intersection of HIV and Methamphetamine Use mfleming Wed, 11/23/2022 - 12:51 Nora's Blog November 28, 2022 Image NIDA Image On World AIDS Day, December 1, we remember those lost to the HIV epidemic, take stock of how far we have come, and map the way forward. In the past decades, scientific and community leadership have achieved great things in helping people with HIV live long, healthy lives, as well as reducing HIV transmission through prevention.

Treatment 52

Treatment Virus Research Drugs 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

NOVEMBER 23, 2022

Annual Drug Patent Expirations for IGALMI Igalmi is a drug marketed by Bioxcel and is included in one NDA. There is one patent protecting this drug. This drug has twenty…. The post New patent for Bioxcel drug IGALMI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug & Device Law

NOVEMBER 25, 2022

We write on the heels of a long weekend layered with dogs and fun. The National Dog Show, which you may have watched on TV yesterday, is held about ten minutes from our house, and a fabulous corded Standard Poodle named Joel , who just happens to be “family” (he is the sire of our gorgeous puppy, Luca ) won Best of Opposite Sex two days running (and stayed overnight with us).

Testimonials 59

Testimonials Doctors International 59

Drug Patent Watch

NOVEMBER 22, 2022

Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are nineteen patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 22, 2022

Annual Drug Patent Expirations for INJECTAFER Injectafer is a drug marketed by Am Regent and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Am Regent drug INJECTAFER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 21, 2022

Annual Drug Patent Expirations for FETROJA Fetroja is a drug marketed by Shionogi Inc and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent for Shionogi Inc drug FETROJA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 21, 2022

Annual Drug Patent Expirations for CAROSPIR Carospir is a drug marketed by Cmp Dev Llc and is included in one NDA. It is available from two suppliers. There are seven…. The post New patent for Cmp Dev drug CAROSPIR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 21, 2022

Annual Drug Patent Expirations for TOBI+PODHALER Tobi Podhaler is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from one supplier. There are…. The post New patent for Mylan Speciality drug TOBI PODHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 21, 2022

Annual Drug Patent Expirations for EMERPHED Emerphed is a drug marketed by Nexus Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Nexus Pharms drug EMERPHED appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 20, 2022

Annual Drug Patent Expirations for SUMAVEL+DOSEPRO Sumavel Dosepro is a drug marketed by Endo Ventures Ltd and is included in one NDA. There are nine patents protecting this drug. SUMAVEL…. The post New patent expiration for Endo Ventures drug SUMAVEL DOSEPRO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 19, 2022

Annual Drug Patent Expirations for INBRIJA Inbrija is a drug marketed by Acorda and is included in one NDA. It is available from one supplier. There are ten patents protecting…. The post New patent expiration for Acorda drug INBRIJA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 19, 2022

Annual Drug Patent Expirations for AMLODIPINE+BESYLATE Amlodipine Besylate is a drug marketed by Synthon Pharms, Accord Hlthcare, Alkem, Amneal Pharms Ny, Apotex, Aurobindo Pharma, Chartwell Rx, China Resources, Cipla, Epic…. The post New patent expiration for Synthon Pharms drug AMLODIPINE BESYLATE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 25, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 25, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 24, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 24, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 23, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 23, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 22, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 22, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 21, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40